Johnson & Johnson stock: CAPLYTA Phase 3 study meets key endpoints
Published on 11/14/2026 at 11:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSJohnson & Johnson advances its pipeline
- Johnson & Johnson reported positive Phase 3 results for CAPLYTA in bipolar mania on November 10.
- A pasritamig and JNJ-9401 combination produced deep PSA reductions in a Phase 1 prostate-cancer study on November 9.
- The prostate-cancer combination is being evaluated in an ongoing Phase 3 study.
Johnson & Johnson reported two notable drug-development updates during the week of November 9 through November 13. On November 10, the company said a second pivotal Phase 3 study of CAPLYTA met its primary and key secondary endpoints in adults with bipolar I disorder and manic episodes. On November 9, it reported early prostate-cancer results for a combination of pasritamig and JNJ-9401.
Johnson & Johnson stock traded at 259.98 euros on Lang & Schwarz at 11:24 CET on Saturday, November 14.
CAPLYTA clears another late-stage test
In its November 10 release, Johnson & Johnson said CAPLYTA improved manic symptoms and overall illness severity versus placebo at Week 3, with improvement seen as early as Day 3. The study found a 3.7-point greater reduction in the Young Mania Rating Scale versus placebo at Week 3. The planned U.S. regulatory submission will cover bipolar mania, while CAPLYTA is already approved for several depressive and schizophrenia indications.
Prostate combination moves to Phase 3
On November 9, a Johnson & Johnson release said 11 of 15 patients in the recommended Phase 1 regimen achieved PSA reductions of at least 50%. Seven patients recorded reductions of at least 90%, and all seven remained on treatment for more than six months without disease progression. The company said the combination is now being evaluated in the Phase 3 KLK2-comPAS study in metastatic castration-resistant prostate cancer.
The findings remain early-stage clinical evidence. The prostate-cancer program and the planned CAPLYTA filing could expand Johnson & Johnson's pipeline if later studies and regulatory reviews confirm the reported results.
The broader market backdrop is covered in Current market reports.
More news and analyses on Johnson & Johnson stock.
Johnson & Johnson at a glance
- Company: Johnson & Johnson
- ISIN: US4781601046
- U.S. ticker: JNJ
- Lang & Schwarz quote: 259.98 euros on November 14, 2026, at 11:24 CET
- Weekly developments: CAPLYTA Phase 3 results and prostate-cancer Phase 1 results
